Chemical Genetic-Mediated Spatial Regulation of Protein Expression in Neurons Reveals an Axonal Function for WldS  by Cohen, Michael S. et al.
Chemistry & Biology
Brief CommunicationChemical Genetic-Mediated Spatial Regulation
of Protein Expression in Neurons Reveals
an Axonal Function for WldS
Michael S. Cohen,1,4,5 Ananda K. Ghosh,1,4 Hyung Joon Kim,2 Noo Li Jeon,3 and Samie R. Jaffrey1,*
1Department of Pharmacology, Weill Medical College, Cornell University, New York, NY 10065, USA
2Department of Biomedical Engineering, University of California, Irvine, Irvine, CA 92697, USA
3Division of World Class University Multiscale Mechanical Design, School of Mechanical & Aerospace Engineering, Seoul National University,
Seoul 151-744, Korea
4These authors contributed equally to this work
5Present address: Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, OR 97239, USA
*Correspondence: srj2003@med.cornell.edu
DOI 10.1016/j.chembiol.2012.01.012SUMMARY
The degeneration of axons is the underlying patho-
logical process of several neurological disorders.
The Wallerian degeneration (WldS) slow protein,
which is primarily nuclear, markedly inhibits axonal
degeneration. Contradictory models have been
proposed to explain its mechanism, including a role
in the nucleus, where it affects gene transcription,
and roles outside the nucleus, where it regulates
unknown effectors. To determine which pool of
WldS accounts for its axon-protective effects, we
developed a strategy to control the spatial expres-
sion of proteins within neurons. This strategy
couples a chemical genetic method to control
protein stability with microfluidic culturing. Using
neurons that are selectively deficient in WldS in
axons, we show that the axonal pool of WldS is
necessary for protection from axon degeneration.
These results implicate an axonal pathway regulated
by WldS that controls axon degeneration.
INTRODUCTION
Axonal degeneration is a prominent feature of several neurode-
generative diseases, including Parkinson’s disease, multiple
sclerosis, and peripheral neuropathies (Coleman and Freeman,
2010). Slow Wallerian degeneration (WldS) mutant mice exhibit
marked protection from axonal degeneration and disease symp-
toms in mouse models of these disorders (Kaneko et al., 2006;
Meyer zu Horste et al., 2011; Sajadi et al., 2004; Samsam
et al., 2003), as well as delayed Wallerian degeneration following
axonal transection (Lunn et al., 1989). The WldS gene encodes
a fusion of nicotinamide mononucleotide adenylyl transferase
(Nmnat1), an NAD+-biosynthetic enzyme, with the N-terminal
70 amino acids of ubiquitin fusion degradation protein-2a
(Ufd2a), an E4 ubiquitin ligase (Mack et al., 2001). The remark-
able protective effects of WldS in mouse models of neurodegen-Chemistry & Biology 19, 179erative diseases have highlighted the importance of determining
the mechanism by which it mediates its effects.
Two different models have been proposed to explain how
WldS protects axons from degeneration. In one model, WldS
was proposed to activate gene expression that protects axons
by increasing nuclear NAD levels (Araki et al., 2004). Themajority
of WldS is in the nucleus and was proposed to regulate SIRT1,
a nucleus-enriched NAD+-dependent histone deacetylase,
which would influence the expression of genes that confer resis-
tance to axonal degeneration (Araki et al., 2004). In a second
model, WldS was proposed to function outside the nucleus
(e.g., in either the cytoplasm or axon itself). In this model, WldS
acts on an unknown nonnuclear target to mediate its effects on
axons. Although only trace levels of extranuclear and axonal
WldS have been detected (Beirowski et al., 2009), WldS mutants
that do not efficiently localize to the nucleus exhibit greater axon-
protective effects than wild-type (Beirowski et al., 2009). These
findings suggest that WldS could function either in the soma or
axons to prevent axon degeneration. A role for WldS in axons
is indirectly suggested by several recent studies: (1) exogenous
application of NAD+, a potential effector of WldS, delays the
degeneration of transected axons (Wang et al., 2005), (2) an
NMNAT1 mutant containing an axon-targeting sequence results
in enhanced axonal protection (Babetto et al., 2010), and (3)
direct delivery of the NMNAT1 protein into severed axons pre-
vented axonal degeneration (Sasaki and Milbrandt, 2010).
Although some of these experiments show that axonal targeting
of NMNAT1 is sufficient for axonal protection, these experiments
do not directly address the mechanism of WldS, which may have
different properties than NMNAT1 (Conforti et al., 2007). The
contradictory models proposed for the action of WldS each
implicate distinct, spatially distributed pools of WldS as medi-
ating its axon-protective effects.
To reconcile these models and directly determine whether
WldS functions in axons or in the soma tomediate axonal protec-
tion, we developed a strategy to spatially regulate the expression
of WldS in neurons. In this approach, a chemical genetic strategy
is coupled to microfluidic neuronal culturing so that proteins are
selectively stabilized or destabilized in either the cell body or
axons. We show that the cell body and axonal pool of diverse
proteins can be targeted, allowing the function of these pools–187, February 24, 2012 ª2012 Elsevier Ltd All rights reserved 179
Figure 1. A Combined Chemical Genetic and Microfluidic Compartmentalization Approach to Regulate WldS Expression in Axons
(A) Schematic representation of the strategy to selectively regulate protein expression in axons. Neurons are cultured in a PDMS-based microfluidic device that
leads to spatial and fluidic isolation of axons from cell bodies. Neurons are infectedwith a lentivirus that expressesWldS fused to EGFP (WldS-EGFP) and amutant
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axons and found that the axonal pool is necessary to mediate
its axon-protective effects.
RESULTS
Combined Chemical Genetic and Microfluidic
Compartmentalization Approach to Regulate Spatial
Expression of Proteins in Neurons
To distinguish between the function of axonal and somal WldS in
axon protection, we sought a strategy for the spatial regulation of
protein expression in neurons. To accomplish this, we devel-
oped a strategy that combines a chemical genetic method to
regulate protein stability (Banaszynski et al., 2006; Iwamoto
et al., 2010) with a microfluidic culturing device to spatially and
fluidically isolate axons from cell bodies (Taylor et al., 2005) (Fig-
ure 1A). The chemical geneticmethod involves fusing a protein of
interest to a destabilization domain (DD), which confers insta-
bility to the fusion protein in cells. The fusion protein is stabilized
by the addition of a small molecule that binds to the DD, protect-
ing it from degradation (Banaszynski et al., 2006). Neurons are
cultured in a polydimethylsiloxane (PDMS)-based microfluidic
culturing device, which comprises a cell body (CB) compartment
and a distal axon (DA) compartment, separated by embedded
microgrooves (10 mm3 450 mm). Importantly, the compartments
are fluidically isolated due to the narrow microgrooves. The
application of a hydrostatic gradient can be used to direct fluid
flow toward one compartment or the other, preventing small
molecules applied to one compartment from readily diffusing
to the other compartment (Hengst et al., 2009; Taylor et al.,
2005). We reasoned that the expression levels of a DD fusion
of WldS in axons can be regulated by application of a DD ligand
to both compartments, in which the DD fusion would be stabi-
lized in both cell bodies and axons, or to the CB compartment
alone, in which the DD fusion would only be stabilized in the
cell body (Figure 1A). It is important to note that application of
the DD ligand to the DA compartment alone would not lead to
selective expression of the DD fusion in axons since the protein
must first be synthesized in the cell body and then transported to
the axon.
We first determined whether the expression of a DD fusion of
EGFP in axons could be selectively regulated by a DD ligand. We
chose the DD ligand/DD system based on a mutant of E. coli di-
hydrofolate reductase (R12Y/Y100I, DDd) (Iwamoto et al., 2010),
which is stabilized by trimethoprim (TMP), as it proved optimal
for use in microfluidic devices (Figure S1 available online).
Embryonic day 15 (E15) rat dorsal root ganglion (DRG) neuronsdihydrofolate reductase domain, which constitutes a DD. WldS fused to the DD (W
TMP, the small molecule DD ligand WldS-EGFP-DD is stabilized and protected f
results in WldS expression in both cell bodies and axons (left). However, selecti
deficient in WldS (right). See also Figure S1.
(B and C) Chemical genetic control of the spatial expression of EGFP in neurons.
DIV5, TMP (300 nM) or vehicle in fresh culturemediumwas added to either the CB
fluorescent images of the CB and DA compartments were taken. EGFP is express
and DA compartment. However, EGFP is not readily detectable in axons of neuro
montages. Scale bar, 50 mm.
(C) The immunofluorescence results in (B) were confirmed via western blotting. Th
4%–12%SDS-PAGE and detected via western blot analysis with antibodies to EG
axonal EGFP expression.
Chemistry & Biology 19, 179were plated in the CB compartment and subsequently infected
with a lentivirus expressing DDd-enhanced green fluorescent
protein (EGFP). Axons begin to cross into the DA compartment
by day in vitro 2 (DIV2) and most neurons proximal to the micro-
grooves exhibit crossed axons by DIV5. When TMP was added
to both the CB and DA compartments, EGFP fluorescence was
observed in both cell bodies and axons (Figures 1B and 1C).
By contrast, application of TMP exclusively to the CB compart-
ment resulted in negligible EGFP expression in axons (Figures
1B and 1C). Importantly, selective application of TMP to the
CB compartment resulted in EGFP expression levels in cell
bodies that was the same as application of TMP to both the
CB compartment and DA compartment (Figures 1B and 1C).
We next determined whether the expression of a DDd fusion
of a neuronal protein could be spatially regulated by TMP using
microfluidic devices. We focused on fragile X mental retarda-
tion protein (FMRP), a regulator of messenger RNA translation
that functions predominately in the soma but is also postulated
to have a role in axons (Antar et al., 2005; Antar et al., 2006).
E15 DRG neurons were infected with a lentivirus expressing
DDd-EGFP-FMRP. This construct was regulated by TMP, as
bath application of TMP substantially increased the expression
of DDd-EGFP-FMRP (Figure S1). Similar to EGFP, the spatial
expression of the FMRP DDd construct could be regulated in
neurons cultured in microfluidic devices. DDd-EGFP-FMRP
was expressed throughout the neuron when TMP was added
to both the CB and axonal compartments. However, when
TMP was added to the CB compartment alone, DDd-EGFP-
FMRP was no longer detected in axons (Figure S1). Taken
together, these results demonstrate a chemical genetic method
to control protein levels in axons without affecting expression
levels in the cell body. Thus, the role of an axonal pool of
a protein can be directly examined independent of the cell
body pool.
Chemical Genetic Control of Axon Growth
To further establish the generalizability of our approach to regu-
late the spatial expression of proteins in neurons, we sought to
determine whether axon growth could be controlled by compart-
mented expression of the small guanosine triphosphatase RhoA.
RhoA is expressed in both the cell body and axons of DRG
neurons and can inhibit axon growth elicited by molecules
such as nerve growth factor (NGF) (Liu et al., 2002; Wu et al.,
2005). Since RhoA regulates actin polymerization, which is
required for axon growth, RhoA may function in axons to restrict
axonal elongation. However, RhoA has been proposed to func-
tion in the cell body to control axon growth (Bertrand et al.,ldS-EGFP-DD) is unstable and is rapidly degraded; however, in the presence of
rom degradation. Application of trimethoprim to the CB and DA compartment
ve application of trimethoprim to the CB compartment alone results in axons
E15 rat DRG neurons were infected with a lentivirus expressing DDd-EGFP. On
compartment alone, or to both the CB and DA compartments. On DIV7, live cell
ed in both the cell bodies and axons in neurons treated with TMP in both the CB
ns treated with TMP only in the CB compartment. The images are presented as
e cell body and axonal material were harvested and proteins were resolved by
FP and actin. Inclusion of TMP in the DA compartment was required tomaintain
–187, February 24, 2012 ª2012 Elsevier Ltd All rights reserved 181
Figure 2. Chemical Genetic Control of RhoA
Activity in Axons
(A) DDd-EGFP-RhoA-CA expression levels can be
regulated by TMP in DRG neurons. On DIV1, E15
rat DRG neurons were infected with a lentivirus
expressing DDd-EGFP-RhoA-CA. On DIV3, TMP
(300 nM) or vehicle was added, and after 24 hr,
cells were harvested and proteins were resolved
by 4%–12% SDS-PAGE and detected via western
blot analysis with antibodies to EGFP and actin.
These data show that TMP can regulate the sta-
bility of DDd-EGFP-RhoA-CA in cultured neurons.
(B and D) Selective expression of RhoA-CA in
axons. On DIV0, E15 rat DRG neurons were in-
fected with a lentivirus expressing DDd-EGFP-
RhoA-CA or treated with vehicle. On DIV2, TMP
(300 nM) or vehicle was added to either the CB or
the DA compartment alone, or to both compart-
ments. After 24 hr, cells were fixed and im-
munolabeled with antibodies against EGFP
(green) and TAU1 (red). (B) Cell bodies in the CB
compartment. (D) Axons in the DA compartment.
Scale bars, 20 mm.
(C and E) Quantification of results from (B) and (D).
The data show that the TMP/DDd system can be
used to spatially control RhoAexpression in axons.
Error bars represent the SEM. n.s., not significant.
***p = 0.0001 (unpaired Student’s t test).
(F) Axon growth can be inhibited by selective
expression of RhoA-CA in axons. On DIV0, E15 rat
DRG neurons were infected with a lentivirus ex-
pressing DDd-EGFP-RhoA-CA or DDd-EGFP. On
DIV2, TMP (300 nM) or vehicle was added to either
the CB or the DA compartment alone or to both
compartments. On DIV3, neuronal outgrowth was
stimulated with NGF (100 ng ml1), and phase-
contrast images were acquired of the same optical
fields at 0 min and 60 min after NGF addition. Error
bars represent the SEM. ***p < 0.0001 (unpaired
Student’s t test); n values listed above the bars
represent the number of axons analyzed.
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in cell bodies can regulate axonal growth rates.
To achieve direct activation of RhoA signaling with TMP inde-
pendent of extracellular inputs, we prepared a DDd fusion of
a constitutively active RhoA mutant, RhoA Q63L (RhoA-CA)
(Subauste et al., 2000). To determine whether TMP can regulate
the expression of RhoA-CA in neurons, E15 rat DRG neurons
were infected with a lentivirus expressing DDd-EGFP-RhoA-
CA. This construct was regulated by TMP, as bath application
of TMP substantially increased the expression of RhoA-CA in
DDd-EGFP-RhoA-CA-expressing neurons (Figure 2A). To deter-
mine whether the expression of DDd-EGFP-RhoA-CA could be
spatially controlled, E15 rat DRG neuronswere cultured inmicro-
fluidic devices and infected with a lentivirus expressing DDd-
EGFP-RhoA-CA. Application of TMP to both the CB and DA
compartments resulted in RhoA-CA expression in both axons
and cell bodies, whereas application of TMP to the CB compart-
ment alone resulted in RhoA-CA expression only in cell bodies,
with negligible levels in axons (Figures 2B–2E).
We next sought to determine the spatial relationship between
RhoA activity and axonal growth. We first examined the role of
RhoA activity in the cell body. To selectively activate RhoA in182 Chemistry & Biology 19, 179–187, February 24, 2012 ª2012 Elsethe cell body, we applied TMP to the CB compartment alone,
which results in activated RhoA expression restricted to the
cell body. Neurons that expressed DDd-EGFP-RhoA-CA solely
in cell bodies exhibited the same NGF-mediated axon growth
rates compared to DDd-EGFP-RhoA-CA-expressing neurons
that were not treated with TMP (Figure 2F). This indicates that
the cell body pool of RhoA is not sufficient to regulate axon
growth.
We next asked whether activation of the axonal pool of RhoA
inhibits axon growth. To assess the role of axonal RhoA, we
compared neurons in which TMP was applied exclusively to
the CB compartment with neurons in which TMP was applied
to both the CB and DA compartments. These treatments
allow us to compare neurons that express DDd-EGFP-RhoA-
CA in the cell body with neurons that express DDd-EGFP-
RhoA-CA in both the cell body and axons. Under these
conditions, neurons expressing DDd-EGFP-RhoA-CA through-
out the axon exhibited significantly reduced axonal growth
compared to neurons expressing DDd-EGFP-RhoA-CA exclu-
sively in the cell body (Figure 2F). Importantly, TMP has no
direct effect on axon growth, as application of TMP to both
the CB and DA compartment did not inhibit axon growth invier Ltd All rights reserved
Figure 3. WldS Expression in Axons Is
Required for Its Axon-Protective Effects
(A) Domain architecture of WldS-EGFP-DDd. Wld
S
is a fusion protein comprising Nmnat1, an NAD+
biosynthetic enzyme, and the N terminus of Ufd2a,
an E4 ubiquitin ligase.
(B) Chemical genetic regulation of WldS levels in
DRG neurons. On DIV3, E15 rat DRG neurons
expressing WldS-EGFP-DDd were treated with
TMP (300 nM) or vehicle for 24 hr. Cells were
harvested and proteinswere resolved by 4%–12%
SDS-PAGE and detected via western blot analysis
with antibodies to EGFP and actin.
(C and E) Selective expression of WldS in axons.
On DIV1, E15 rat DRG neurons were infected with
a lentivirus expressing WldS-EGFP-DDd or treated
with vehicle. On DIV2, TMP (300 nM) or vehicle
was added to either the CB or the DA compart-
ment alone, or to both compartments. After 24 hr,
cells were fixed and immunolabeled with anti-
bodies against EGFP (green) and GAP43 (red). (C)
Cell bodies in the CB compartment. (E) Axons in
the DA compartment. Scale bars, 20 mm.
(D and F) Quantification of results from (C) and (E).
The data show that the TMP/DDd system can be
used to spatially control WldS expression in axons.
Error bars represent the SEM. n.s., not significant.
***p = 0.0001 (unpaired Student’s t test).
(G) WldS expression in axons is required for
protection from VB-mediated axon degradation.
On DIV1, neurons were infected with WldS-EGFP-
DDd-expressing lentivirus, and TMP (300 nM) or
vehicle was added 24 hr later to either the CB
compartment or to both compartments. On DIV5,
vinblastine (50 nM) or vehicle was added to the CB
compartment to disrupt microtubule-dependent
transport into axons. Phase-contrast images (203
objective) of the DA compartment were acquired
72 hr later. Application of VB to the CB compart-
ment led to axonal degradation, which is detected
as fragmented axons in the phase images. Appli-
cation of TMP to both the CB and DA com-
partment, which stabilizes WldS-EGFP-DDd
throughout the neuron, protects axons from
degeneration. However, CB application of TMP,
which stabilizes WldS-EGFP-DDd only in the cell
body, did not protect axons. These results
demonstrate that the axonal pool of WldS-EGFP-
DDd mediates its protective effects. See also Fig-
ure S2.
(H) Quantification of results shown in (G). The extent of axon degeneration was determined by calculating the degeneration index (100 axons from three fields per
condition in each of two independent experiments). Data are presented as the mean ± SEM. n.s., not significant. *p = 0.01 (unpaired Student’s t test).
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results demonstrate that the axonal pool of RhoA is required
to regulate axon growth.
WldS Functions in Axons to Mediate Its Axon-Protective
Effects
Having established a combined chemical genetic and microflui-
dic strategy to regulate the spatial expression and activity of
proteins in neurons, we next wanted to examine which pool
(i.e., cell body or axonal) of WldS is required for its protective
effects on axons. Since the N terminus of WldS is important for
its function (Conforti et al., 2007), we prepared a C-terminalChemistry & Biology 19, 179fusion of WldS with EGFP-DDd (Figure 3A). The expression of
the WldS-EGFP-DDd construct could be regulated by bath appli-
cation of TMP in DRG neurons (Figure 3B).
To determine whether the expression of WldS-EGFP-DDd
could be spatially controlled, E15 rat DRG neurons were cultured
in microfluidic devices and infected with a lentivirus expressing
WldS-EGFP-DDd. Application of TMP to either the CB compart-
ment alone or to both the CB and DA compartments resulted in
similar levels of WldS-EGFP-DDd in the nucleus (Figures 3C and
3D). However, only when TMPwas added to both compartments
could we detect WldS-EGFP-DDd expression in axons, albeit
weak (Figures 3E and 3F).–187, February 24, 2012 ª2012 Elsevier Ltd All rights reserved 183
Figure 4. WldS Expression in Axons Is
Required for Protection against Wallerian
Degeneration
(A) Amodifiedmicrofluidic device for growing DRG
explant cultures. The standard device (left) was
modified to generate the explant culture device
(right), which contains an open area to place the
explants adjacent to the microgrooves (inset).
Axons emanating from the explant efficiently grow
through themicrogrooves to the DA compartment.
(B) Chemically distinct microenvironments can be
achieved in the explant culture. On DIV14 Alexa
Fluor-647 hydrazide (20 mg/ml) was added to the
neurite compartment for 24 hr. The image is an
overlay of the phase contrast and fluorescence
through the Cy5 filter at 24 hr. Scale bars, 50 mm.
(C) Quantification of results shown in (B). The
fluorescence intensity profiles were obtained from
the gray horizontal lines in (B).
(D) An axonal role for WldS in protecting axons
against Wallerian degeneration. DRG explants
grown in explant culture devices were infected
withWldS-EGFP-DDd-expressing lentivirus, and TMP (300 nM) or vehicle was added 24 hr later to either the CB compartment or to both compartments. On DIV5,
axons were physically severed to initiate axon degeneration.
(E) Quantification of results shown in (D). Axon degeneration indices were calculated as described in Figure 3E (100 axons from two fields per condition in each of
two independent experiments). Data are presented as the mean ± SEM. *p = 0.009 (unpaired Student’s t test). Phase-contrast images (203 objective) of the DA
compartment were acquired 96 hr later. Application of TMP to both the CB and DA compartment, which stabilizes WldS-EGFP-DDd throughout the neuron,
protects axons from Wallerian degeneration. However, CB application of TMP, which stabilizes WldS-EGFP-DDd only in the cell body, did not protect axons.
These results demonstrate that the axonal pool of WldS-EGFP-DDd mediates its protective effects.
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sufficient to protect axons from degeneration. Previous studies
have shown that WldS delays axon degeneration in neuropa-
thies associated with defects in microtubule-based axonal
transport (Ferri et al., 2003). To model impairment of axonal
transport, we selectively applied vinblastine (VB), a microtubule
depolymerization agent, to the CB compartment. We reasoned
that this treatment would disrupt microtubule-based transport
of proteins into axons required to maintain axon viability.
Although it is formally possible that some VB could diffuse
intracellularly from cell bodies to axons in the DA compart-
ment, it is unlikely that this VB would have any effect on
axon degradation, since it would equilibrate into the volume
of the media in the DA compartment, substantially reducing
its effective concentration. Indeed, VB treatment of the CB
compartment resulted in axon degeneration, with the first
signs of axonal degeneration seen at 8 hr and complete axonal
fragmentation seen at 24 hr (Figure S2). These data indicate
that microtubule disruption in the cell body elicits subsequent
axonal degeneration. Application of TMP to the CB compart-
ment alone, which limits the expression of WldS-EGFP-DDd
to cell bodies, did not significantly delay this form of axonal
degeneration (Figures 3G and 3H). These results show that
despite the high level of WldS in the cell body, its expression
in this compartment does not confer protection from axonal
degeneration mediated by microtubule disruption in the cell
body.
Given that the cell body pool of WldS is not sufficient to protect
axons from degeneration mediated by microtubule disruption, it
is possible that the trace amounts of WldS in axons (Beirowski
et al., 2009) mediates its axon-protective effects. We therefore
determined whether the axonal pool of WldS is required to184 Chemistry & Biology 19, 179–187, February 24, 2012 ª2012 Elseprotect axons from VB-mediated degeneration. In contrast to
application of TMP to the CB compartment alone, which limits
WldS to the cell body, application of TMP to both the CB and
DA compartments delayed this form of axonal degeneration
(Figures 3G and 3H). Together, these results demonstrate that
expression of WldS in axons is required for protection against
VB-mediated axon degeneration.
To further examine the function of WldS in axons, we next
determined whether the axonal pool of WldS is required to
protect axons from Wallerian degeneration induced by axonal
transection. WldS protects axons from Wallerian degeneration
in vivo (Beirowski et al., 2009; Lunn et al., 1989) and in DRG
explant cultures in vitro (Araki et al., 2004; Conforti et al.,
2007). In order to culture DRG explants in microfluidic devices,
we modified the standard device to create an open area to place
the explants adjacent to the microgrooves (Figure 4A). Given this
alteration, wewanted to determinewhether these explant culture
devices are able to maintain fluidic isolation between the two
compartments. To assess fluidic isolation between the CB and
DA compartment in these devices, we incubated the CB
compartment with Alexa Fluor-647 hydrazide (20 mg ml1), a
low molecular weight fluorescent dye. Even after a 48 hr incuba-
tion, only a trace amount (1%) of the dye was detected in the
DA compartment (Figures 4B and 4C).
We next asked whether the axonal pool of WldS accounts for
its inhibitory effects onWallerian degeneration. Axon transection
was initiated by removing the explant, and axon degeneration
was monitored. Similar to results obtained from VB-mediated
axon degeneration experiments, application of TMP to both
the CB and DA compartments was required to protect against
axonal degeneration after transection in neurons expressing
WldS-EGFP-DDd (Figures 4D and 4E). Application of TMP tovier Ltd All rights reserved
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axon degeneration (Figures 4D and 4E). Taken together, these
results demonstrate that the cell body pool of WldS does not
protect against axon degeneration, while the much smaller
axonal pool of WldS is required for axonal protection against
axon degeneration.
DISCUSSION
Although the protective effect of WldS on axon degeneration is
widely appreciated, its subcellular site of action is controversial.
Although previous studies have shown that targeting WldS, or its
enzymatic domain, NMNAT1, to axons was sufficient to protect
against axonal degeneration (Babetto et al., 2010; Beirowski
et al., 2009; Sasaki and Milbrandt, 2010), direct evidence for
a requirement for an axonal localization of WldS is lacking. This
is due to the lack of a method to selectively deplete WldS from
axons without affecting cell body expression. Here, we have
developed a combined chemical genetic and microfluidic
approach to generate neurons selectively deficient in the axonal
pool of WldS. Using this method, we show that despite its abun-
dant expression in the nucleus, WldS is required in axons to
mediate its axon-protective effect. Thus, the chemical genetic
approach described here provides formal proof of the require-
ment for axonally localizedWldS. The requirement for WldS func-
tion in axons implies that its downstream effectors are not in the
nucleus as previously suggested (Araki et al., 2004), but rather
axonally localized. Identifying the axon as the subcellular site
of action of WldS function lays the groundwork for elucidating
the mechanism of axonal WldS-mediated axon protection.
What are the potential ways in which axonal WldS protects
axons against degeneration? One potential mechanism is
through its known role in NAD+ biosynthesis. NAD+ activates
the sirtuin family of lysine deacetylases, which could trigger the
deacetylation of a protein that accounts for the effects of WldS.
Previous studies implicated SIRT1, which is localized to the
nucleus, as the downstream effector of WldS (Araki et al.,
2004). However, the data presented here suggest that an axo-
nally localized sirtuin is a more likely effector of WldS. Alterna-
tively, the production of NAD+ by axonal WldS could affect
energy metabolism that could influence axon viability (Yan
et al., 2010). Another possibility is that WldS acts as a neuropro-
tective molecule via a protein chaperone function, as was
recently demonstrated for Nmnat in Drosophila (Zhai et al.,
2008). Binding to and stabilization of an axonal protein may
lead to its protective effects in axons. Delineating the axon-
protective pathway mediated by axonal WldS may reveal new
therapeutic strategies for neurodegenerative diseases.
Because neurons exhibit spatially segregated subcellular
compartments, such as axons and cell bodies, a method to
selectively target specific subcellular pools of proteins is essen-
tial for understanding the mechanism of proteins in neurons. By
specifically targeting different intracellular pools, their function
can be addressed, and the subcellular site of the downstream
signaling pathways that they regulate can be identified. Indeed,
numerous signaling proteins exhibit localization in both the cell
body and axonal compartments of neurons, including the
RNA-binding proteins survival of motor neuron (SMN) (Burghes
and Beattie, 2009) and HuD (Smith et al., 2004). In some cases,Chemistry & Biology 19, 179even transcription factors have been localized to axons (Cox
et al., 2008). The functional role of the axonal pool of many of
these proteins has not been addressed. The technique
described here allows protein regulation in a spatially restricted
manner in neurons. To our knowledge, this study provides the
first general strategy to establish the functional role of the axonal
pool of a protein. We envision that the combined chemical
genetic and microfluidic approach to regulate the spatial ex-
pression of proteins in neurons described here will be useful
to assess the axon-specific function of numerous proteins be-
sides WldS.
SIGNIFICANCE
Amajor contributor to the pathology of various neurodegen-
erative diseases, including Parkinson’s disease andmultiple
sclerosis, is the degeneration of axons. The WldS protein
exhibits remarkable axon-protective effects in mouse
models of these diseases, thus garnering much interest in
its therapeutic potential. However, the mechanism of
WldS-mediated axon protection is not well understood.
Although WldS is predominately expressed in the nucleus
and is thought to function in this compartment to protect
axons, recent evidence suggests that trace amounts of
extranuclear (i.e., cytoplasmic or axonal) WldS is the func-
tionally relevant pool. Directly determining the subcellular
site of actionWldS is essential to understanding its function,
yet this has remained a formidable challenge. Using
a combined chemical genetic andmicrofluidic compartmen-
talization approach, we demonstrate a general strategy to
determine a protein’s subcellular site of action in neurons.
We used this strategy to identify the subcellular compart-
ment WldS functions in to protect axons from degeneration.
By generating neurons selectively deficient in its axonal
pool, we show that the somal pool of WldS is not sufficient
to protect against axon degeneration; rather, the axonal
pool is required for its axon-protective effects. These results
not only provide formal proof that an axonal pathway medi-
ated by WldS can inhibit axon degeneration, they also
provide the foundation to identify the axonal, downstream
mediator of WldS. Additionally, we anticipate that the
general strategy to spatially control protein expression in
neurons described here will be an essential tool to better
understand protein function in neurons.
EXPERIMENTAL PROCEDURES
Compartmented Neuronal Culture in Microfluidic Devices
DRG neurons and explants were prepared as described previously (Wu et al.,
2005). A total of 150 ml per reservoir of culture medium was added to the DA
compartment followed by plating 4 3 104 dissociated E15 rat DRG neurons
or DRG explants (100-200 mm in diameter) in the CB compartment. After allow-
ing 15 min for neuronal attachment to the coverslips, culture medium con-
taining either 50 ng ml1 2.5S NGF (Invitrogen) or 20 ng ml1 NGF (R&D
Systems) was added to the CB compartment (150 ml per reservoir). Unless
otherwise noted, medium was exchanged with fresh culture medium on DIV2.
Compartmented Regulation of EGFP Expression in DRG Neurons
E15 rat DRG neurons (4 3 104 cells per device in CB compartment) were
cultured in microfluidic devices. Six hours after plating, neurons were infected
with a lentivirus expressing DDd-EGFP. On DIV5, TMP (300 nM) or vehicle in–187, February 24, 2012 ª2012 Elsevier Ltd All rights reserved 185
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compartments. TMP in the CB compartment was fluidically isolated the DA
compartment by maintaining a volume difference of 100 ml, such that the DA
axon compartment contained 100 ml more media than the CB compartment.
Medium was replaced every 24 hr with fresh culture medium containing
TMP or vehicle as described above. On DIV7, live cell fluorescent images of
the CB and DA compartments were taken. Images are presented as
montages. Cells were then harvested for western blot analysis.
Outgrowth Assays and Compartmented Regulation of
DDd-EGFP-RhoA-CA
Dissociated E15 rat DRG neurons (4 3 104 cells per device in CB compart-
ment) were cultured in microfluidic devices grown on either coated plastic
dishes (outgrowth assays) or glass coverslips (immunofluorescence). Six
hours after plating, neurons were infected (or not) with a lentivirus expressing
either DDd-EGFP (outgrowth assays only) or DDd-EGFP-RhoA-CA or treated
with vehicle. On DIV2, TMP (300 nM) or vehicle in fresh culture medium with
reduced NGF (5 ng ml1) was added to either the CB or the DA compartment
alone, or to both compartments. This concentration of NGF reduces basal
axon growth without compromising survival (Hengst et al., 2009). On DIV3,
medium from the DA compartment was removed and replaced with fresh
medium containing 100 ng ml1 NGF to stimulate axon growth, and either
TMP (300 nM) or vehicle. Phase-contrast images were acquired from the
same optical fields at 0 min and 60 min to monitor growth rates of the same
axons. Cells grown on glass coverslips were processed for immunofluores-
cence analysis as described.
Vinblastine-Mediated Axon Degeneration and Compartmented
Regulation of WldS-EGFP-DDd
Dissociated E15 rat DRG neurons (43 104 cells per device applied to the CB
compartment) were cultured in microfluidic devices on coated plastic dishes.
Twenty-four hours after plating, neurons were infected (or not) with a lentivirus
expressing WldS-EGFP-DDd, or treated with vehicle. On DIV2, TMP (300 nM)
or vehicle in fresh culture medium was added to either the CB or the DA
compartment alone, or to both compartments. On DIV5, vinblastine (50 nM)
was added to the CB compartment. Medium in all reservoirs was replaced
after 48 hr with fresh culture medium containing vinblastine or vehicle, and
TMP or vehicle. Seventy-two hours after the addition of vinblastine, phase-
contrast images (203 objective) of the DA compartment were acquired.
The extent of axon degeneration was determined by calculating the degen-
eration index as previously described (100 axons from three fields per condi-
tion) (Sasaki et al., 2009). Briefly, the phase-contrast images were converted to
binary images in which the axons were made black and the background was
made white. The total axon area was defined as the total number of black
pixels. Degenerated axons exhibit a particulate structure due to fragmentation.
Degeneration was detected using the particle analyzer module in ImageJ. The
degeneration index was the ratio of fragmented axons area over total axon
area. Data analysis was performed blind to experimental conditions.
Transection Assay in DRG Explant Cultures
E15 rat DRG explants (4-5 per device) were plated in the CB compartment of
the modified explant culture device on coated plastic dishes. Twenty-four
hours after plating, explants were infected (or not) with lentivirus expressing
WldS-EGFP-DDd, or treated with vehicle. On DIV2, TMP (300 nM) or vehicle
in fresh culture medium was added to either the CB or the DA compartment
alone or to both compartments. On DIV5, the axons were transected in the
CB compartment using a sterile surgical needle. Medium in all reservoirs
was replaced after 48 hr with fresh culture medium containing TMP or vehicle.
Ninety-six hours posttransection, phase-contrast images (203 objective) of
the DA compartment were acquired. The extent of axon degeneration was
determined by calculating the degeneration index as previously described
(100 axons from two fields per condition) (Sasaki et al., 2009). Data analysis
was performed blind to experimental conditions.
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